These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26835238)

  • 41. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
    Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
    J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
    Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
    Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Efficacy and safety of eribulin for metastatic breast cancer patients].
    Okishiro M; Egawa C; Kusama H; Matsushita K; Hashimoto N; Kawashima H; Mukai Y; Hamanaka M; Takeno A; Sakisaka H; Nakahira S; Taniguchi H; Suzuki R; Takeda Y; Kato T; Tamura S; Takatsuka Y
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):215-9. PubMed ID: 24743200
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study.
    Oruc Z; Kaplan MA; Geredeli C; Yildirim Sari N; Ozaslan E; Aytekin A; Tamer Elkiran E; Koca S; Dogan M; Turan N; Yuce O; Sevinc A; Ercelep O; Isikdogan A
    J BUON; 2019; 24(5):1876-1883. PubMed ID: 31786850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.
    Yuan P; Hu X; Sun T; Li W; Zhang Q; Cui S; Cheng Y; Ouyang Q; Wang X; Chen Z; Hiraiwa M; Saito K; Funasaka S; Xu B
    Eur J Cancer; 2019 May; 112():57-65. PubMed ID: 30928806
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital.
    Poletti P; Ghilardi V; Livraghi L; Milesi L; Rota Caremoli E; Tondini C
    Future Oncol; 2014 Feb; 10(2):233-9. PubMed ID: 24490609
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Efficacy, safety and cost of eribulin in patients with metastatic breast cancer].
    Paillard MJ; Curtit E; Dobi E; Mansi L; Bazan F; Villanueva C; Chaigneau L; Montcuquet P; Meneveau N; Thiery-Vuillemin A; Nerich V; Pivot X
    Bull Cancer; 2015 Sep; 102(9):737-48. PubMed ID: 26022285
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.
    Fabi A; Moscetti L; Ciccarese M; Caramanti M; Salesi N; La Verde N; Russillo M; Generali D; Scandurra G; Vari S; Pacetti U; Cognetti F; Giannarelli D
    Future Oncol; 2015; 11(3):431-8. PubMed ID: 25675124
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
    Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
    Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
    Iwasa T; Tsurutani J; Watanabe S; Kato R; Mizuno Y; Kojima Y; Takashima T; Matsunami N; Morimoto T; Yamamura J; Ohtani S; Tanabe Y; Yoshinami T; Takano T; Komoike Y; Nakagawa K
    BMC Cancer; 2019 Oct; 19(1):962. PubMed ID: 31619197
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody-Drug Conjugate Therapy.
    Goyal RK; Zhang J; Davis KL; Sluga-O'Callaghan M; Kaufman PA
    Breast Cancer (Dove Med Press); 2023; 15():855-865. PubMed ID: 38020049
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805).
    Stein MN; Chen YH; Carducci MA; Hudes GR; Lerma PM; Tan WW; Dalune R; Rowland KM; Kuzel TM; DiPaola RS
    Am J Clin Oncol; 2019 Apr; 42(4):375-381. PubMed ID: 30789412
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.
    Watanabe J; Ito Y; Ohsumi S; Mizutani M; Tashiro H; Sakurai K; Takahashi M; Saito T; Tsurutani J; Mukai H; Yoshinami T; Takao S; Yamamoto Y; Matsuoka T; Iwase H; Iwata H; Nakamura S; Saeki T
    Invest New Drugs; 2017 Dec; 35(6):791-799. PubMed ID: 28660549
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
    Scarpace SL
    Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in therapy: eribulin improves survival for metastatic breast cancer.
    Morris PG
    Anticancer Drugs; 2010 Nov; 21(10):885-9. PubMed ID: 20838209
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.
    Sakaguchi K; Nakatsukasa K; Koyama H; Kato M; Sakuyama A; Matsuda T; Tsunoda N; Fujiwara I; Yamaguchi M; Tanaka H; Onishi K; Onishi M; Yoshino Y; Kikuchi T; Taguchi T
    Anticancer Res; 2018 Jul; 38(7):4073-4081. PubMed ID: 29970533
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.
    Lorusso V; Cinieri S; Latorre A; Porcu L; Del Mastro L; Puglisi F; Barni S
    Future Oncol; 2017 May; 13(11):971-978. PubMed ID: 28326833
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical evaluation of eribulin mesylate for the treatment of metastatic breast cancer].
    Matsuzaki H; Tohnosu N; Yoshiwara C; Maruyama T; Tanaka H; Natsume T; Miyazaki A; Sato Y; Ohta T; Yamamoto Y; Aikawa M; Ohtsuka R; Yanagihara A; Iwata K; Shiratori T; Miyazawa Y
    Gan To Kagaku Ryoho; 2014 Apr; 41(4):455-9. PubMed ID: 24743360
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy.
    Doherty MK; Morris PG
    Int J Womens Health; 2015; 7():47-58. PubMed ID: 25610001
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
    Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
    BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.